In a recent federal court development, attorneys for Luigi Mangione are pushing to have several charges dropped in the assassination case of UnitedHealthcare CEO Brian Thompson. These charges tie back to the December 2024 incident where Thompson was fatally shot outside a Manhattan hotel. As reported by CBS News, Mangione's defense team has filed motions arguing that their client should not be held accountable for the death penalty relating to federal charges. They contend that Mangione was not read his rights before being questioned and that his backpack, containing a gun and ammunition, was searched without a warrant.
Following the national shockwave caused by the high-profile murder, Mangione’s lawyers have been working to undermine the federal case against him, claiming procedural missteps that may lend Mangione a legal advantage. According to the papers filed, as obtained by Business Insider, the attorneys argue that Count Three, the only charge in the indictment eligible for the death penalty, along with Count Four, should be dismissed on the grounds that the stalking offenses outlined in Counts One and Two do not qualify as crimes of violence. Additionally, the wording used to describe the ammunition found at the murder scene has been associated with criticism of U.S. health insurers.
The discussion surrounding the potential for Mangione to face the death penalty has gained considerable attention. His legal counsel has requested that U.S. District Judge Margaret Garnett not only dismiss some charges but also bar the government from pursuing the death penalty against Mangione. The outcome of this request has yet to be determined by the court.
Last month, Mangione experienced some relief in his legal battles when New York Supreme Court Justice Gregory Carro dismissed two top terrorism charges against him for being legally insufficient. Facing multiple prosecutions encompassing federal and state charges, Mangione has held firm to his plea of not guilty across all fronts. The murder took place shortly before Thompson was scheduled to participate in his company’s investor conference, a detail that has maintained public interest in the case, as reported by CBS News.
